A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

• Register: ClinicalTrials.gov
• Last refreshed on: 24 January 2022
• Main ID: NCT03626012
• Date of registration: 07/08/2018
• Prospective Registration: Yes
• Primary sponsor: Biogen
• Public title: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
• Scientific title: A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
• Date of first enrolment: September 10, 2018
• Target sample size: 106
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03626012
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
• Phase: Phase 1

Countries of recruitment

Canada, Ireland, Netherlands, Switzerland, United Kingdom, United States

Contacts

• Name: Medical Director
• Affiliation: Biogen

Key inclusion & exclusion criteria

Key Inclusion Criteria:

- Ability of the participant to understand the purpose and risks of the study, to
provide signed and dated informed consent, and to authorize the use of confidential
health information in accordance with national and local participant privacy
regulations; or, in the event of the participant's physical incapacity to sign, to
confirm that understanding and consent orally to a legally authorized representative
(LAR) for the express purpose of having said informed consent and authorization signed
on his/her behalf.

- All participants of childbearing potential must agree to practice highly effective
contraception during the study and be willing and able to continue contraception for 5
months after their last dose of study treatment.

- Must meet the possible, laboratory-supported probable, probable, or definite criteria
for diagnosing ALS according to the World Federation of Neurology El Escorial criteria
and have documentation of a clinical genetic test demonstrating the presence of a
pathogenic mutation in C9ORF72.

- Slow vital capacity (SVC) = 50% of predicted value as adjusted for sex, age, and
height (from the sitting position).

- Participants taking concomitant riluzole at study entry must be on a stable dose for =
30 days prior to the first dose of study treatment (Day 1).

- Participants taking concomitant edaravone at study entry must be on a stable dose for
= 60 days prior to the first dose of study treatment (Day 1).

- ALS Cognitive Behavioral Screen (ALS-CBS) score = 11 for the cognitive portion; = 33
for the behavioral portion.

- Medically able to undergo the study procedures, and to adhere to the visit schedule at
the time of study entry, as determined by the Investigator.

- Screening values of coagulation parameters including platelet count, international
normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin
time (APTT) should be within normal ranges.

- Has an informant/caregiver who, in the Investigator's judgment, has frequent and
sufficient contact with the participant as to be able to provide accurate information
about the participant's cognitive and functional abilities at Screening.

Key Exclusion Criteria:

- History of drug abuse or alcoholism = 6 months of Screening that would limit
participation in the study, as determined by the Investigator.

- Tracheostomy.

- Prescreening ALSFRS-R slope less than 0.4 points/month, where prescreening ALSFRS-R
slope is defined as follows: (48 - ALSFRS-R score at Screening) / (months from date of
symptom onset to date of Screening).

- History of or positive test result at Screening for human immunodeficiency virus. .

- History of, or positive test result at Screening for, hepatitis C virus antibody.

- Treatment with another investigational drug or biological agent within 1 month of
Screening or 5 half-lives of study agent, whichever is longer.

- Treatment with an antiplatelet or anticoagulant therapy that cannot safely be
interrupted for lumbar puncture (LP) according to local standard of care and/or
institutional guidelines, in the opinion of the Investigator or Prescriber.

- Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing
system during the study period.

- Female participants who are pregnant or currently breastfeeding.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Amyotrophic Lateral Sclerosis

Intervention(s)

Drug: BIIB078

Drug: Placebo

Primary Outcome(s)

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time Frame: Baseline through End of Study (Approximately Day 323)]

Secondary Outcome(s)

Change from Baseline in Muscle Strength [Time Frame: Baseline up to Day 260]

Change from Baseline in Bulbar Strength [Time Frame: Baseline up to Day 260]

Maximum Observed Concentration (Cmax) [Time Frame: Baseline and at multiple time points up to Day 260]

Change from Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Scores [Time Frame: Baseline up to Day 323]

Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) [Time Frame: Baseline and at multiple time points up to Day 260]

Terminal Elimination Half-Life (t 1/2) [Time Frame: Baseline and at multiple time points up to Day 260]

Serum BIIB078 Concentration [Time Frame: Baseline and at multiple time points up to Day 260]

AUC from Time 0 to Time of the Last Measurable Concentration (AUClast) [Time Frame: Baseline and at multiple time points up to Day 260]

Change from Baseline in Percent of Predicted Slow Vital Capacity (SVC) [Time Frame: Baseline up to Day 260]

Time to Reach Cmax (Tmax) [Time Frame: Baseline and at multiple time points up to Day 260]

Secondary ID(s)

2017-000294-36

245AS101

Source(s) of Monetary Support

Please refer to primary and secondary sponsors